{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:18:20Z","timestamp":1770250700554,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04408-3","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T18:24:54Z","timestamp":1767810294000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-omics analysis of key lipid metabolism-related genes involved in the anti-hepatocellular carcinoma effect of dihydroartemisinin"],"prefix":"10.1007","volume":"17","author":[{"given":"Jiaqi","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yicheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junxia","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"4408_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02075-w","volume":"10","author":"J Zheng","year":"2025","unstructured":"Zheng J, et al. Hepatocellular carcinoma: signaling pathways and therapeutic advances. Signal Transduct Target Ther. 2025;10:35. https:\/\/doi.org\/10.1038\/s41392-024-02075-w.","journal-title":"Signal Transduct Target Ther"},{"key":"4408_CR2","doi-asserted-by":"publisher","DOI":"10.17998\/jlc.2025.07.25","author":"MH Lee","year":"2025","unstructured":"Lee MH. Public health strategies for hepatocellular carcinoma: from risk factors to prevention and control. J Liver Cancer. 2025. https:\/\/doi.org\/10.17998\/jlc.2025.07.25.","journal-title":"J Liver Cancer"},{"key":"4408_CR3","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1080\/14737159.2021.1987217","volume":"21","author":"NT Moldogazieva","year":"2021","unstructured":"Moldogazieva NT, Zavadskiy SP, Sologova SS, Mokhosoev IM, Terentiev AA. Predictive biomarkers for systemic therapy of hepatocellular carcinoma. Expert Rev Mol Diagn. 2021;21:1147\u201364. https:\/\/doi.org\/10.1080\/14737159.2021.1987217.","journal-title":"Expert Rev Mol Diagn"},{"key":"4408_CR4","doi-asserted-by":"publisher","first-page":"7088","DOI":"10.7150\/thno.99197","volume":"14","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, et al. Decreased lncRNA HNF4A-AS1 facilitates resistance to sorafenib-induced ferroptosis of hepatocellular carcinoma by reprogramming lipid metabolism. Theranostics. 2024;14:7088\u2013110. https:\/\/doi.org\/10.7150\/thno.99197.","journal-title":"Theranostics"},{"key":"4408_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/biom12111700","author":"D Zuo","year":"2022","unstructured":"Zuo D. Screening for lipid-metabolism-related genes and identifying the diagnostic potential of ANGPTL6 for HBV-related early-stage hepatocellular carcinoma. Biomolecules. 2022. https:\/\/doi.org\/10.3390\/biom12111700.","journal-title":"Biomolecules"},{"key":"4408_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-76578-5","volume":"14","author":"L Hao","year":"2024","unstructured":"Hao L, Li S, Hu X. Expression of lipid-metabolism genes is correlated with immune microenvironment and predicts prognosis of hepatocellular carcinoma. Sci Rep. 2024;14:25705. https:\/\/doi.org\/10.1038\/s41598-024-76578-5.","journal-title":"Sci Rep"},{"key":"4408_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02274-1","volume":"24","author":"L Huang","year":"2025","unstructured":"Huang L, et al. Modulating lipid metabolism by nanoparticles (NPs)-mediated ACSL3 silencing to inhibit hepatocellular carcinoma growth and metastasis. Mol Cancer. 2025;24:73. https:\/\/doi.org\/10.1186\/s12943-025-02274-1.","journal-title":"Mol Cancer"},{"key":"4408_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2021.153913","volume":"96","author":"L Hao","year":"2022","unstructured":"Hao L, et al. Dihydroartemisinin reduced lipid droplet deposition by YAP1 to promote the anti-PD-1 effect in hepatocellular carcinoma. Phytomedicine. 2022;96:153913. https:\/\/doi.org\/10.1016\/j.phymed.2021.153913.","journal-title":"Phytomedicine"},{"key":"4408_CR9","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/ptr.6332","volume":"33","author":"X Shi","year":"2019","unstructured":"Shi X, et al. Dihydroartemisinin, an antimalarial drug, induces absent in melanoma 2 inflammasome activation and autophagy in human hepatocellular carcinoma HepG2215 cells. Phytother Res. 2019;33:1413\u201325. https:\/\/doi.org\/10.1002\/ptr.6332.","journal-title":"Phytother Res"},{"key":"4408_CR10","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202200171R","volume":"36","author":"Y Guo","year":"2022","unstructured":"Guo Y, et al. Dihydroartemisinin promoted FXR expression independent of YAP1 in hepatocellular carcinoma. FASEB J. 2022;36:e22361. https:\/\/doi.org\/10.1096\/fj.202200171R.","journal-title":"FASEB J"},{"key":"4408_CR11","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2021.12914","volume":"22","author":"L Hao","year":"2021","unstructured":"Hao L, et al. Anti-malarial drug dihydroartemisinin downregulates the expression levels of CDK1 and CCNB1 in liver cancer. Oncol Lett. 2021;22:653. https:\/\/doi.org\/10.3892\/ol.2021.12914.","journal-title":"Oncol Lett"},{"key":"4408_CR12","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1002\/ptr.7695","volume":"37","author":"Q Peng","year":"2023","unstructured":"Peng Q, et al. Dihydroartemisinin broke the tumor immunosuppressive microenvironment by inhibiting YAP1 expression to enhance anti-PD-1 efficacy. Phytother Res. 2023;37:1740\u201353. https:\/\/doi.org\/10.1002\/ptr.7695.","journal-title":"Phytother Res"},{"key":"4408_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11418-022-01641-2","volume":"77","author":"Q Peng","year":"2023","unstructured":"Peng Q, et al. Dihydroartemisinin inhibited the Warburg effect through YAP1\/SLC2A1 pathway in hepatocellular carcinoma. J Nat Med. 2023;77:28\u201340. https:\/\/doi.org\/10.1007\/s11418-022-01641-2.","journal-title":"J Nat Med"},{"key":"4408_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113594","volume":"144","author":"L Pu","year":"2025","unstructured":"Pu L, et al. Genetic association of tertiary lymphoid structure-related gene signatures with HCC based on Mendelian randomization and machine learning and construction of prognosis model. Int Immunopharmacol. 2025;144:113594. https:\/\/doi.org\/10.1016\/j.intimp.2024.113594.","journal-title":"Int Immunopharmacol"},{"key":"4408_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2023.106724","volume":"157","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Wang S, Zhu Z, Nie B. Identification of potential feature genes in non-alcoholic fatty liver disease using bioinformatics analysis and machine learning strategies. Comput Biol Med. 2023;157:106724. https:\/\/doi.org\/10.1016\/j.compbiomed.2023.106724.","journal-title":"Comput Biol Med"},{"key":"4408_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/15330338231219352","volume":"23","author":"J Zou","year":"2024","unstructured":"Zou J, et al. Prediction model of ocular metastases in gastric adenocarcinoma: machine learning-based development and interpretation study. Technol Cancer Res Treat. 2024;23:15330338231219352. https:\/\/doi.org\/10.1177\/15330338231219352.","journal-title":"Technol Cancer Res Treat"},{"key":"4408_CR17","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gkw1118","volume":"45","author":"Y Wang","year":"2017","unstructured":"Wang Y, et al. PubChem bioassay: 2017 update. Nucleic Acids Res. 2017;45:D955-d963. https:\/\/doi.org\/10.1093\/nar\/gkw1118.","journal-title":"Nucleic Acids Res"},{"key":"4408_CR18","doi-asserted-by":"publisher","first-page":"W357","DOI":"10.1093\/nar\/gkz382","volume":"47","author":"A Daina","year":"2019","unstructured":"Daina A, Michielin O, Zoete V. Swisstargetprediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019;47:W357-64. https:\/\/doi.org\/10.1093\/nar\/gkz382.","journal-title":"Nucleic Acids Res"},{"key":"4408_CR19","doi-asserted-by":"publisher","first-page":"W356","DOI":"10.1093\/nar\/gkx374","volume":"45","author":"X Wang","year":"2017","unstructured":"Wang X, et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017;45:W356-w360. https:\/\/doi.org\/10.1093\/nar\/gkx374.","journal-title":"Nucleic Acids Res"},{"key":"4408_CR20","doi-asserted-by":"publisher","first-page":"D138","DOI":"10.1093\/nar\/gkad965","volume":"52","author":"E Clough","year":"2024","unstructured":"Clough E, et al. NCBI GEO: archive for gene expression and epigenomics data sets: 23-year update. Nucleic Acids Res. 2024;52:D138-d144. https:\/\/doi.org\/10.1093\/nar\/gkad965.","journal-title":"Nucleic Acids Res"},{"key":"4408_CR21","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk D, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51:D638-d646. https:\/\/doi.org\/10.1093\/nar\/gkac1000.","journal-title":"Nucleic Acids Res"},{"key":"4408_CR22","doi-asserted-by":"publisher","first-page":"5734","DOI":"10.1111\/bph.70215","volume":"182","author":"M Posta","year":"2025","unstructured":"Posta M, Gy\u0151rffy B. Pathway-level mutational signatures predict breast cancer outcomes and reveal therapeutic targets. Br J Pharmacol. 2025;182:5734\u201347. https:\/\/doi.org\/10.1111\/bph.70215.","journal-title":"Br J Pharmacol"},{"key":"4408_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adh9940","volume":"16","author":"J Ding","year":"2024","unstructured":"Ding J, et al. Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese population. Sci Transl Med. 2024;16:eadh9940. https:\/\/doi.org\/10.1126\/scitranslmed.adh9940.","journal-title":"Sci Transl Med"},{"key":"4408_CR24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.toxlet.2012.06.001","volume":"212","author":"H Tojima","year":"2012","unstructured":"Tojima H, et al. Ligand dependent hepatic gene expression profiles of nuclear receptors CAR and PXR. Toxicol Lett. 2012;212:288\u201397. https:\/\/doi.org\/10.1016\/j.toxlet.2012.06.001.","journal-title":"Toxicol Lett"},{"key":"4408_CR25","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1016\/j.apsb.2021.10.014","volume":"11","author":"J Jin","year":"2021","unstructured":"Jin J, et al. Proteomics and metabolic phenotyping define principal roles for the aryl hydrocarbon receptor in mouse liver. Acta pharmaceutica Sinica B. 2021;11:3806\u201319. https:\/\/doi.org\/10.1016\/j.apsb.2021.10.014.","journal-title":"Acta pharmaceutica Sinica. B"},{"key":"4408_CR26","doi-asserted-by":"publisher","first-page":"7681","DOI":"10.7150\/thno.74974","volume":"12","author":"C Wu","year":"2022","unstructured":"Wu C, et al. AKR1C3-dependent lipid droplet formation confers hepatocellular carcinoma cell adaptability to targeted therapy. Theranostics. 2022;12:7681\u201398. https:\/\/doi.org\/10.7150\/thno.74974.","journal-title":"Theranostics"},{"key":"4408_CR27","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.2174\/0113816128287535240429043610","volume":"30","author":"Y Wan","year":"2024","unstructured":"Wan Y, et al. Exploring the molecular mechanisms of Huaier on modulating metabolic reprogramming of hepatocellular carcinoma: a study based on network pharmacology, molecular docking and bioinformatics. Curr Pharm Des. 2024;30:1894\u2013911. https:\/\/doi.org\/10.2174\/0113816128287535240429043610.","journal-title":"Curr Pharm Des"},{"key":"4408_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04729-0","author":"M Is\u0131yel","year":"2025","unstructured":"Is\u0131yel M, Ceylan H, Demir Y. Integrated bioinformatics and molecular docking \u0131dentify CCNB1, CDK1, and CYP1A2 as therapeutic targets of phytochemicals in hepatocellular carcinoma. Naunyn Schmiedebergs Arch Pharmacol. 2025. https:\/\/doi.org\/10.1007\/s00210-025-04729-0.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"4408_CR29","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.7150\/thno.49368","volume":"11","author":"J Yu","year":"2021","unstructured":"Yu J, et al. CYP1A2 suppresses hepatocellular carcinoma through antagonizing HGF\/MET signaling. Theranostics. 2021;11:2123\u201336. https:\/\/doi.org\/10.7150\/thno.49368.","journal-title":"Theranostics"},{"key":"4408_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153863","volume":"11","author":"J Ren","year":"2016","unstructured":"Ren J, et al. Cytochrome P450 1A2 metabolizes 17\u03b2-estradiol to suppress hepatocellular carcinoma. PLoS One. 2016;11:e0153863. https:\/\/doi.org\/10.1371\/journal.pone.0153863.","journal-title":"PLoS One"},{"key":"4408_CR31","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41388-020-01545-z","volume":"40","author":"J Yu","year":"2021","unstructured":"Yu J, et al. Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma. Oncogene. 2021;40:492\u2013507. https:\/\/doi.org\/10.1038\/s41388-020-01545-z.","journal-title":"Oncogene"},{"key":"4408_CR32","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1124\/dmd.124.001665","volume":"52","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, et al. Epigenetic activation of cytochrome P450 1A2 sensitizes hepatocellular carcinoma cells to sorafenib. Drug Metab Dispos. 2024;52:555\u201364. https:\/\/doi.org\/10.1124\/dmd.124.001665.","journal-title":"Drug Metab Dispos"},{"key":"4408_CR33","doi-asserted-by":"publisher","first-page":"22058","DOI":"10.18632\/oncotarget.25178","volume":"9","author":"R Ashida","year":"2018","unstructured":"Ashida R, et al. The down-regulation of the CYP2C19 gene is associated with aggressive tumor potential and the poorer recurrence-free survival of hepatocellular carcinoma. Oncotarget. 2018;9:22058\u201368. https:\/\/doi.org\/10.18632\/oncotarget.25178.","journal-title":"Oncotarget"},{"key":"4408_CR34","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/cam4.1299","volume":"7","author":"X Wang","year":"2018","unstructured":"Wang X, et al. The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma. Cancer Med. 2018;7:966\u201380. https:\/\/doi.org\/10.1002\/cam4.1299.","journal-title":"Cancer Med"},{"key":"4408_CR35","first-page":"53","volume":"1","author":"N Iizuka","year":"2004","unstructured":"Iizuka N, et al. Altered levels of cytochrome P450 genes in hepatitis B or C Virus-infected liver identified by oligonucleotide microarray. Cancer Genomics Proteomics. 2004;1:53\u20138.","journal-title":"Cancer Genomics Proteomics"},{"key":"4408_CR36","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1038\/s41388-022-02379-7","volume":"41","author":"D Pan","year":"2022","unstructured":"Pan D, et al. AKR1C3 regulated by NRF2\/MAFG complex promotes proliferation via stabilizing PARP1 in hepatocellular carcinoma. Oncogene. 2022;41:3846\u201358. https:\/\/doi.org\/10.1038\/s41388-022-02379-7.","journal-title":"Oncogene"},{"key":"4408_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.823491","volume":"12","author":"J Zheng","year":"2022","unstructured":"Zheng J, Yang Z, Li Y, Yang L, Yao R. Knockdown of AKR1C3 promoted sorafenib sensitivity through inhibiting the phosphorylation of AKT in hepatocellular carcinoma. Front Oncol. 2022;12:823491. https:\/\/doi.org\/10.3389\/fonc.2022.823491.","journal-title":"Front Oncol"},{"key":"4408_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04202-w","volume":"7","author":"C Xie","year":"2017","unstructured":"Xie C, et al. LC-MS\/MS quantification of sulfotransferases is better than conventional immunogenic methods in determining human liver SULT activities: implication in precision medicine. Sci Rep. 2017;7:3858. https:\/\/doi.org\/10.1038\/s41598-017-04202-w.","journal-title":"Sci Rep"},{"key":"4408_CR39","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s10495-024-01938-5","volume":"29","author":"H Peng","year":"2024","unstructured":"Peng H, et al. An integrated investigation of sulfotransferases (SULTs) in hepatocellular carcinoma and identification of the role of SULT2A1 on stemness. Apoptosis. 2024;29:898\u2013919. https:\/\/doi.org\/10.1007\/s10495-024-01938-5.","journal-title":"Apoptosis"},{"key":"4408_CR40","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/carcin\/bgz107","volume":"40","author":"SR Lee","year":"2019","unstructured":"Lee SR, et al. Sex hormone-binding globulin suppresses NAFLD-triggered hepatocarcinogenesis after menopause. Carcinogenesis. 2019;40:1031\u201341. https:\/\/doi.org\/10.1093\/carcin\/bgz107.","journal-title":"Carcinogenesis"},{"key":"4408_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-024-00569-9","volume":"19","author":"T Wang","year":"2024","unstructured":"Wang T, et al. Construction of a prognostic model based on disulfidptosis-related genes and identification of CCNA2 as a novel biomarker for hepatocellular carcinoma. Biol Direct. 2024;19:128. https:\/\/doi.org\/10.1186\/s13062-024-00569-9.","journal-title":"Biol Direct"},{"key":"4408_CR42","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8755263","volume":"2022","author":"X Pang","year":"2022","unstructured":"Pang X, Wan W, Wu X, Shen Y. The novel action of miR-193b-3p\/CDK1 signaling in HCC proliferation and migration: a study based on bioinformatic analysis and experimental investigation. Int J Genomics. 2022;2022:8755263. https:\/\/doi.org\/10.1155\/2022\/8755263.","journal-title":"Int J Genomics"},{"key":"4408_CR43","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.bbrc.2017.03.075","volume":"486","author":"C Chen","year":"2017","unstructured":"Chen C, et al. AURKA promotes cancer metastasis by regulating epithelial-mesenchymal transition and cancer stem cell properties in hepatocellular carcinoma. Biochem Biophys Res Commun. 2017;486:514\u201320. https:\/\/doi.org\/10.1016\/j.bbrc.2017.03.075.","journal-title":"Biochem Biophys Res Commun"},{"key":"4408_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2022.100697","volume":"27","author":"Y Shan","year":"2022","unstructured":"Shan Y, et al. IGF-1 contributes to liver cancer development in diabetes patients by promoting autophagy. Ann Hepatol. 2022;27:100697. https:\/\/doi.org\/10.1016\/j.aohep.2022.100697.","journal-title":"Ann Hepatol"},{"key":"4408_CR45","doi-asserted-by":"publisher","first-page":"368","DOI":"10.2174\/0113892029277262231108105441","volume":"24","author":"YM Xiong","year":"2023","unstructured":"Xiong YM, et al. Aberrant expressions of PSMD14 in tumor tissue are the potential prognostic biomarkers for hepatocellular carcinoma after curative resection. Curr Genomics. 2023;24:368\u201384. https:\/\/doi.org\/10.2174\/0113892029277262231108105441.","journal-title":"Curr Genomics"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04408-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04408-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04408-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T11:16:29Z","timestamp":1770203789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04408-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4408"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04408-3","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and\u00a0consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"237"}}